Moderna and MSD have announced follow-up data from the Phase IIb clinical trial evaluating cancer vaccine mRNA-4157 in combination with MSD s Keytruda in patients with resected high-risk.
A vaccine shows promising results in treating the most deadly form of skin cancer, Moderna and Merck announced on Thursday. Those with severe melanomas who received the vaccine and Merck's cancer drug Keytruda were 49% less likely to die or have their cancer come back after three years than those who were given only Keytruda,
mRNA cancer vaccine shows positive results in melanoma patients europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.
In this analysis conducted with a median follow-up of approximately three years, mRNA-4157 + Keytruda demonstrated a clinically significant improvement in recurrence-free survival , reducing the risk.